Dystonic and dyskinetic symptoms associated with antipsychotic medication and involving the pharynx and larynx may present a risk for aspiration and/asphyxiation'F, Previously it had been shown that terminal seizures were sometimes associated with sudden death in cases currently receiving antipsychotic medication", We now present a case in which the adverse synergistic effects of a convulsion coupledwith a drug-induced parkinsonian syndrome involving the respiratory muscles is highlighted.
Case report
A 19-year-old woman was admitted 7 weeks prior to her death to the general medical ward in a mute catatonic state. She was initially investigated for a possible underlying neurological disorder but this proved negative. She was then given chlorpromazine (100 mg three times a day) plus fluphenazine decanoate intramuscular injections (125 mg/week for 3 weeks following admission). At the end of 3 weeks she was no longer catatonic nor mute but was grossly psychotic and difficult to manage in the general ward. She had also developed severe dystonic side effects, which restricted her breathing when the rigidity was severe. She received biperiden (5 mg intramuscular as required) which controlled her dystonia. Her slow progress led to a cessation of all previous neuroleptic treatment from the 4th week of her stay and clozapine (300 mg nocte) was substituted and the biperiden was continued. Two weeks later (ie 6 weeks from admission) her response remained minimal and flupenthixol intramuscularly (40 mg biweekly) was added to her medication. At the same time biperiden was increased (5 mg intramuscularly daily) because her dystonic reactions continued intermittently. However her general condition was still only ameliorated to a minimal degree. On the day of her death she had a dystonic reaction in the morning which was controlled by a biperiden injection. She recovered fully, ate lunch, but at 1500 h she again became dystonic and suffered a major grand mal convulsion (never having had a fit prior to this) before she could receive further biperiden. Death followed within 15 min, apparently from asphyxia. There was no clinical evidence of aspiration and no post mortem examination was carried out.
Discussion
In this case it was likely that the preceding dystonic reaction was related to the fatal outcome following the fit, in that it could have seriously impaired respiratory function to such an extent that the patient was unable to recover from the fit. It would appear that any epileptic patient on major tranquillizers or any patient suffering with fits while on neuroleptics may well be at greater risk of a fatal outcome from a seizure. It is possible that this could result from the adverse synergism between the drug-induced extrapyramidal symptoms, especially when affecting the respiratory muscles, and a concomitant convulsion. In view of the well known lowering of seizure threshold common to most antipsychotic agents currently in use", it might be worthwhile to combine an anti-epileptic agent with such medication on a routine basis particularly iflarger than normal doses of neuroleptics are administered. Moreover, in patients who are prone to develop parkinsonian side effects, switching exclusively to an agent like clozapine might be prophylactic. The latter agent has been shown to have minimal central antidopaminergic effects? and would therefore be expected to produce much fewer extrapyramidal side-effects.
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Case report
A 78-year-old retired miner was admitted with a 2-week history of progressive weakness of limbs, constipation and retention of urine. There was no preceding history of viral illness. He was on captopril 25 mg twice daily and hydrochlorothiazide 5 mg daily for hypertension. On examination he was heavily built, apyrexial and had a blood pressure of 170/85 mmHg. Cardiovascular, respiratory and abdominal examination were all normal. Neurological examination revealed higher functions and cranial nerves to be unaffected. Muscular fasciculations were present in all limbs, with power grade 3/5 proximally and 4/5 distally. There was generalized areflexia and both plantars were equivocal. Sensation was intact.
Laboratory data: haemoglobin 14.1 g/dl, whole blood count 10.2x10 9 /L with lymphocytes 4.78x10 9 /L, platelets 216 x 10 9 /L, erythrocyte sedimentation rate 10 mmlh and peripheral blood smear showed abnormal mononuclear cells. Biochemical results showed plasma sodium 121 mmol/l, potassium 3.05 mmol/l, urea, creatinine and glucose were normal. The CSF was clear, sterile with normal cell counts and a protein level of 1.1 gil and IgG of 0.1 gil. Monospot test was negative, viral titres were insignificant and blood culture sterile. Bone marrow examination showed malignant lymphoproliferative morphology suggestive of hairy cell leukaemia. Whole blood count cell markers in the peripheral blood confirmed B cell monoclonal proliferation (CD22· activated B cells 96%, CD19-pre B cells 71% and lambda 80%) and a reactive T cell subpopulation (CD4-0KT4 24% and CD8·0KT8 4%). Electromyography and nerve conduction studies were reported as showing severe motor and sensory
